Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Dutka

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Circulation. Cardiovascular Imaging|February 8, 2014
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery diseaseLiam M McCormick, Anna C Kydd, Philip A Read, et al.
Pacing and Clinical Electrophysiology : PACE|July 30, 2011
Cardiac resynchronization therapy optimization using noninvasive cardiac output measurementFakhar Z Khan, Munmohan S Virdee, John Hutchinson, et al.
JACC. Cardiovascular Interventions|April 20, 2010
Stunning and cumulative left ventricular dysfunction occurs late after coronary balloon occlusion in humans insights from simultaneous coronary and left ventricular hemodynamic assessmentStephen P Hoole, Patrick M Heck, Paul A White, et al.
Basic Research in Cardiology|August 30, 2002
Immunocytochemical evidence for inducible nitric oxide synthase and cyclooxygenase-2 expression with nitrotyrosine formation in human hibernating myocardiumChristopher S R Baker, David P Dutka, Domenico Pagano, et al.
Pacing and Clinical Electrophysiology : PACE|January 7, 2011
The impact of the right ventricular lead position on response to cardiac resynchronization therapyFakhar Z Khan, Pegah Salahshouri, Rudy Duehmke, et al.
Journal of the American College of Cardiology|March 13, 2012
Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trialFakhar Z Khan, Mumohan S Virdee, Christopher R Palmer, et al.
JACC. Cardiovascular Interventions|February 22, 2015
Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilizationLiam M McCormick, Stephen P Hoole, Paul A White, et al.
Coronary Artery Disease|May 15, 2009
Primary coronary microvascular dysfunction and poor coronary collaterals predict post-percutaneous coronary intervention cardiac necrosisStephen P Hoole, Paul A White, Patrick M Heck, et al.
Circulation|February 4, 2009
Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trialStephen P Hoole, Patrick M Heck, Linda Sharples, et al.
European Journal of Heart Failure|April 24, 2009
Remote ischaemic pre-conditioning does not attenuate ischaemic left ventricular dysfunction in humansStephen P Hoole, Sadia N Khan, Paul A White, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Circulation. Cardiovascular Imaging|February 8, 2014
Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery diseaseLiam M McCormick, Anna C Kydd, Philip A Read, et al.
Pacing and Clinical Electrophysiology : PACE|July 30, 2011
Cardiac resynchronization therapy optimization using noninvasive cardiac output measurementFakhar Z Khan, Munmohan S Virdee, John Hutchinson, et al.
JACC. Cardiovascular Interventions|April 20, 2010
Stunning and cumulative left ventricular dysfunction occurs late after coronary balloon occlusion in humans insights from simultaneous coronary and left ventricular hemodynamic assessmentStephen P Hoole, Patrick M Heck, Paul A White, et al.
Basic Research in Cardiology|August 30, 2002
Immunocytochemical evidence for inducible nitric oxide synthase and cyclooxygenase-2 expression with nitrotyrosine formation in human hibernating myocardiumChristopher S R Baker, David P Dutka, Domenico Pagano, et al.
Pacing and Clinical Electrophysiology : PACE|January 7, 2011
The impact of the right ventricular lead position on response to cardiac resynchronization therapyFakhar Z Khan, Pegah Salahshouri, Rudy Duehmke, et al.
Journal of the American College of Cardiology|March 13, 2012
Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trialFakhar Z Khan, Mumohan S Virdee, Christopher R Palmer, et al.
JACC. Cardiovascular Interventions|February 22, 2015
Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilizationLiam M McCormick, Stephen P Hoole, Paul A White, et al.
Coronary Artery Disease|May 15, 2009
Primary coronary microvascular dysfunction and poor coronary collaterals predict post-percutaneous coronary intervention cardiac necrosisStephen P Hoole, Paul A White, Patrick M Heck, et al.
Circulation|February 4, 2009
Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trialStephen P Hoole, Patrick M Heck, Linda Sharples, et al.
European Journal of Heart Failure|April 24, 2009
Remote ischaemic pre-conditioning does not attenuate ischaemic left ventricular dysfunction in humansStephen P Hoole, Sadia N Khan, Paul A White, et al.
Pageof 6